Phase 4 N=49 Compare Anti-inflammatory Dentifrices
Gingivitis
Primary: Gingival Index (GI) — 1.04; 1.01 units on a scale — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=70 Efficacy of Anthocyanin Mouthrinse for Oral Anti-inflammation From Orthodontic Treatment
Inflammation of Mouth · Acute Mucous Inflammation
Primary: Wound Size (mm^2) Reduction — 11.26; 8.92 mm^2
N/A N=25 Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
Cystic Fibrosis
Primary: Neutrophil Delivery to the Oral Mucosa Using a Non-invasive Mouthwash Technique — 6.4; -19.6; -28.4 % change in mean PMN counts: B vs T
Phase 4 N=49 Evaluate Inflammation Caused by Gingivitis in Adults
Gingivitis
Primary: Level of Gingival Crevicular Fluid Interleukin - 1 (GCF IL-1) at 2 Hours — 492.2; 326.3 Micrograms — p=0.05
N/A N=158 A Clinical Trial to Test the Effect of Marketed Mouth Rinses on Decreasing Plaque and Gum Inflammation
Plaque · Gingivitis
Primary: Whole Mouth Mean Modified Gingival Index (MGI) at Week 3 — 2.004; 1.770; 1.807 units on a scale — p=<0.001
Phase 2 N=40 Cox-2 Inhibition in Radiation-induced Oral Mucositis
Oral Mucositis
Primary: Clinical Oral Mucosal Injury Score at Cumulative Radiation Dose of 5000 cGy — 1.42; 1.36 units on a scale
N/A N=96 Oral Tissue Tolerance of a Mouthrinse
Dental Health
Primary: Change in Tooth Color as Represented by ΔE at 8 Weeks Post Baseline From the CIElab Assessment — 0.909; 1.035 units on a scale — p=0.168
N/A N=80 Oral Irritation Study of Two Experimental Mouthrinses
Oral Manifestations
Primary: Percentage of Participants With an Abnormal Condition by Anatomical Site at Screening — 0; 0; 0; 0 Percentage of Participants
N/A N=69 IFI16 is a Periodontitis Modulating Protein
Severe Periodontitis · Acute Inflammatory Response
Primary: Change in Absent in Melanoma 2 (AIM2) mRNA Expression Levels — 0.37; 0.65 fold change — p=0.3
N/A N=32 Induced Gingivitis & Intra-oral Imaging
Plaque Induced Gingivitis
Primary: Change From Baseline Gingivitis at Day 14 as Measured by Non-invasive Microimaging and Gingival Index. — 0.6; 0.15 units on a scale
N/A N=61 Trial of Toothpaste to Reduce Plaque and Inflammation
Plaque · Inflammation
Primary: Change in Oral Plaque — -1.05; -0.03 log(percentage) — p=0.001
Phase 2 N=50 Herbal Mouthrinse for Oral Mucositis Study
Oral Mucositis
Primary: Maximum Change in Mean Mouth and Throat Soreness (MTS) Score From Baseline Through Weeks of Radiation Therapy Using the MTS Question of the Modified Oral Mucositis Daily…
Early Phase 1 N=35 Dose-dependent Anti-inflammatory Effects of Vitamin D in a Human Gingivitis Model
Gingivitis
Primary: Proportion of Sites That Bleed on Probing
Phase 2 N=37 Therapeutic Effects of "Ibuprofen, Diphenhydramine and Aluminium MgS" on Recurrent Aphthous Stomatitis
Aphthous Stomatitis
Primary: Effect of Ibuprofen, Diphenhydramine and Aluminium MgS Measured on Decrease in Pain Level and Burning Sensation — 3.176; 3.821 scores in Visual Analogue Scale
N/A N=32 Study of the Anti-Inflammatory Effects of Colgate Total® During an Experimental Gingivitis Model
Gingivitis
Primary: Change From Baseline in Plaque Index (Silness & Loe 1964) to Day 35 — 0.37; 0.44; 1.24; 1.49 units on a scale
Phase 4 N=60 Local Minocycline to Reduce Future Inflammation and Bone Loss in Periodontal Maintenance Patients
Moderate to Advanced Chronic Periodontitis
Primary: Change in Interproximal Bone Height Loss, Probing Depth and Clinical Attachment Level Over 24 Months — 3.78; 3.87; 3.57; 3.8 mm
Phase 2 N=60 Green Tea Lozenges for the Management of Dry Mouth
Xerostomia · Sjogren Syndrome · Dry Mouth
Primary: Change in Salivary Flow From Baseline — 0.17; 0.10; 0.66; 0.04 ml/min
N/A N=120 Should Maxillary Buccal Infiltration Anesthesia be Given in a Closed Mouth Technique?
Anesthesia, Local · Pain Control
Primary: Patient Pain Perception — 32.6; 25 millimeters on a visual analogue scale
Phase 2 N=86 Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
Advanced Breast Cancer
Primary: Number of Participants With Stomatitis Grade ≥ 2 — 2; 83; 1 Participants — p=<0.001
Phase 2 N=40 Povidone-Iodine Oral Rinse Study
COVID-19
Primary: [PCR Saliva] Percent Change From Baseline Ct Viral Targets — 5.8; 1.3 % Change from Baseline Cycle Threshold — p=0.287
Phase 2 N=59 Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer
Head and Neck Neoplasms · Mucositis
Primary: Incidence of Severe OM During Radiation Therapy in Subjects Receiving a Cumulative IMRT Dose of at Least 55 Gy — 15; 9; 10; 12 Participants
Phase 2 N=29 Dexamethasone Solution and Dexamethasone in Mucolox™
Oral Lichen Planus · Mucous Membrane Pemphigoid · Pemphigus Vulgaris
Primary: Mean Change From Baseline in Oral Pain Scores on the Visual Analog Scale (VAS) at 4 Weeks — 6.3; 4.4 score on a scale
Phase 3 N=73 Clinical Research Study Efficacy of a Prototype Oral Rinse
Dental Plaque
Primary: Gingival Index — 1.90; 1.84 Units on a scale — p=0.005
N/A N=128 Inflammation and the Heart
Rheumatoid Arthritis
Primary: Left Ventricular Mass Indexed to BSA, g/m^2 — 43.8; 42.2 g/m^2
Phase 2 N=127 Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis
Gingival Inflammation
Primary: Incidence of Adverse Events — 19; 10; 3 Participants
N/A N=230 Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2)
COVID-19 · Coronavirus Infection · SARS CoV 2 Infection
Primary: Change in Quantitative Polymerase Chain Reaction (qPCR) From Baseline to 30 Minutes — 0.0345; -0.5577; -1.4789; 0.2339 natural log copies/20μL sample — p=0.59
Phase 1 N=20 Fluoride Retention in the Mouth of Older Adults
Hyposalivation
Primary: Fluoride Concentration in Dental Biofilm Fluid at Baseline — 0.24; 0.22 parts per million (ppm) of fluoride — p=0.8412
Phase 3 N=48 Reducing Bacteria That Cause Tooth Decay
Caries, Dental · Cariostatic Agents
Primary: Microbial Levels — 11; 7; 15; 15 Participants — p=0.35
N/A N=20 Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome
Esophageal Adenocarcinoma · Barrett's Esophagus · Reflux Esophagitis
Primary: Reduction of F. Nucleatum in Saliva
Phase 1 N=48 The Effect of Palatal Brushing on Denture Stomatitis
Denture Stomatitis
Primary: Palatal Inflammation — 3; 3; 2.5; 2 units on a scale — p=<0.0001